Suraj Kalia

“So, Quentin, forgive me, many calls going on at the same time, so I must have probably missed this. Is the value proposition for Vidal Connect really about the Vidal Connect MCT product?”

“So, Olivia, when you say a new site comes online with, let's say, three identified patients, is your approach also really about four to five unit upfront sales?”

“David Zagrin, can you hear me all right? Yes, good morning, Suraj. Gentlemen, thank you for all the comments on navigating these temporary headwinds. Darren, one question for you and payment one for you, I'll pose them both up front.”

“Obviously, a fantastic quarter, Quentin. Maybe you could help us understand, Quentin, you guys are the de facto standard of care on long-term monitoring. For ZOAT in particular, or the MCOT category in particular, I'm curious if you could give us some additional color.”

“Mick, can you give us your perspective on the AHRQ report and any counter messaging or quantification of impact? And second part: the SaaS business was a tailwind for margins and top-line growth previously; over the last four quarters it seems to be less of a tailwind.”